Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	417.3	389.13	290.52	50.7	-	-
Revenue Growth	25.15%	33.95%	473.02%	-	-	-
Cost of Revenue	24.34	23.05	20.06	3.09	-	-
Gross Profit	392.96	366.08	270.45	47.61	-	-
Selling, General & Admin	155.2	146.74	113.63	98.29	77.74	40.39
Research & Development	59.12	58.05	53.58	46.43	42.46	27.88
Other Operating Expenses	-	-	37.5	12.5	25	-
Total Operating Expenses	214.32	204.79	204.71	157.22	145.2	68.28
Operating Income	178.64	161.3	65.75	-109.62	-145.2	-68.28
Interest Income	28.68	28.18	29.61	22.51	5.22	0.2
Interest Expense	-	-	-	-	-	-1.49
Other Non-Operating Income (Expense)	-	-	-	100	-	-
Total Non-Operating Income (Expense)	28.68	28.18	29.61	122.51	5.22	-1.3
Pretax Income	207.32	189.47	95.36	12.9	-139.98	-69.57
Provision for Income Taxes	-17.72	-15.36	6.2	1.97	-	-
Net Income	225.03	204.83	89.16	10.93	-139.98	-69.57
Net Income to Common	225.03	204.83	89.16	10.93	-139.98	-69.57
Net Income Growth	81.53%	129.74%	715.58%	-	-	-
Shares Outstanding (Basic)	29	29	29	27	25	22
Shares Outstanding (Diluted)	30	30	30	28	25	22
Shares Change	0.88%	0.71%	7.16%	8.87%	14.85%	18.15%
EPS (Basic)	7.75	7.08	3.12	0.40	-5.49	-3.13
EPS (Diluted)	7.48	6.84	3.00	0.39	-5.49	-3.13
EPS Growth	79.81%	128.00%	669.23%	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	237.38	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Growth	83.56%	58.51%	-	-	-	-
Free Cash Flow Per Share	7.89	6.31	4.01	-3.63	-6.02	-5.24
Gross Margin	94.17%	94.08%	93.09%	93.90%	-	-
Operating Margin	42.81%	41.45%	22.63%	-216.21%	-	-
Profit Margin	53.92%	52.64%	30.69%	21.56%	-	-
FCF Margin	56.88%	48.55%	41.02%	-198.43%	-	-
EBITDA	185.28	167.85	72.46	-103.71	-141.81	-65.51
EBITDA Margin	44.40%	43.13%	24.94%	-204.55%	-	-
EBIT	178.64	161.3	65.75	-109.62	-145.2	-68.28
EBIT Margin	42.81%	41.45%	22.63%	-216.21%	-	-
Effective Tax Rate	-8.54%	-8.11%	6.50%	15.24%	0.00%	0.00%

SEC Filings: 10-K · 10-Q